• Consensus Rating: Hold
  • Consensus Price Target: $128.25
  • Forecasted Upside: 40.69%
  • Number of Analysts: 15
  • Breakdown:
  • 2 Sell Ratings
  • 4 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.92 (-1.00%)

This chart shows the closing price for AMED by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amedisys Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMED and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMED

Analyst Price Target is $128.25
▲ +40.69% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Amedisys in the last 3 months. The average price target is $128.25, with a high forecast of $190.00 and a low forecast of $85.00. The average price target represents a 40.69% upside from the last price of $91.16.

This chart shows the closing price for AMED for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 15 contributing investment analysts is to hold stock in Amedisys. This rating has held steady since September 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/25/2023BenchmarkLower TargetBuy$135.00 ➝ $120.00Low
1/23/2023Credit Suisse GroupLower TargetOutperform$140.00 ➝ $115.00Low
1/19/2023OppenheimerLower TargetOutperform$145.00 ➝ $125.00Low
1/5/2023SVB LeerinkLower TargetMarket Perform$96.00 ➝ $85.00Low
11/11/2022StephensLower TargetEqual Weight$122.00 ➝ $106.00Low
11/4/2022UBS GroupLower Target$88.00Low
11/4/2022CowenLower Target$103.00Low
11/2/2022Jefferies Financial GroupReiterated RatingBuy ➝ Buy$150.00Low
11/1/2022SVB LeerinkLower TargetMarket Perform$116.00 ➝ $96.00Low
11/1/2022StephensBoost TargetEqual Weight$105.00 ➝ $122.00Low
10/31/2022Royal Bank of CanadaLower TargetOutperform$165.00 ➝ $139.00Low
10/28/2022BarclaysLower TargetOverweight$154.00 ➝ $126.00Low
10/28/2022StephensLower TargetEqual Weight$120.00 ➝ $105.00Low
10/28/2022Truist FinancialLower TargetBuy$140.00 ➝ $130.00Low
10/28/2022OppenheimerLower TargetOutperform$175.00 ➝ $145.00Low
10/27/2022Raymond JamesDowngradeOutperform ➝ Market PerformLow
10/24/2022Deutsche Bank AktiengesellschaftLower TargetBuy$175.00 ➝ $165.00Low
10/5/2022Truist FinancialLower TargetBuy$150.00 ➝ $140.00Low
10/3/2022BenchmarkLower TargetBuy$165.00 ➝ $135.00Low
8/9/2022CowenLower Target$125.00N/A
8/2/2022UBS GroupDowngradeNeutral ➝ Sell$145.00 ➝ $95.00Low
7/29/2022Royal Bank of CanadaLower Target$199.00 ➝ $165.00Low
7/29/2022OppenheimerLower Target$200.00 ➝ $175.00Low
7/14/2022Truist FinancialLower TargetBuy$175.00 ➝ $150.00Low
6/28/2022Stifel NicolausInitiated CoverageHold$128.00Low
6/28/2022Jefferies Financial GroupReiterated RatingBuy$200.00Low
6/21/2022SVB LeerinkLower TargetMarket Perform$117.00 ➝ $107.00Low
6/21/2022Bank of AmericaDowngradeNeutral ➝ Underperform$145.00 ➝ $102.00Low
6/21/2022Deutsche Bank AktiengesellschaftLower TargetBuy$210.00 ➝ $175.00Low
6/21/2022Truist FinancialLower TargetBuy$200.00 ➝ $175.00Low
6/21/2022StephensLower TargetEqual Weight$155.00 ➝ $125.00Low
5/27/2022SVB LeerinkLower TargetMarket Perform$131.00 ➝ $117.00Low
4/29/2022OppenheimerReiterated RatingOutperform$200.00Low
4/29/2022Deutsche Bank AktiengesellschaftLower Target$230.00 ➝ $210.00Medium
4/29/2022Raymond JamesLower Target$200.00 ➝ $180.00Medium
4/7/2022Jefferies Financial GroupReiterated RatingBuy ➝ Buy$200.00High
3/1/2022UBS GroupUpgradeSell ➝ Neutral$152.00 ➝ $168.00Medium
2/25/2022Royal Bank of CanadaLower TargetOutperform$221.00 ➝ $199.00High
2/25/2022Credit Suisse GroupLower TargetOutperform$200.00 ➝ $195.00High
2/25/2022Truist FinancialLower TargetBuy$210.00 ➝ $200.00High
2/25/2022OppenheimerLower TargetOutperform$225.00 ➝ $200.00High
2/25/2022Raymond JamesLower TargetOutperform$225.00 ➝ $200.00High
2/25/2022BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$210.00 ➝ $190.00High
2/24/2022BenchmarkLower TargetBuy$200.00 ➝ $175.00High
2/18/2022SVB LeerinkBoost TargetMarket Perform$145.00 ➝ $147.00Low
12/21/2021BarclaysLower TargetOverweight$236.00 ➝ $213.00High
11/8/2021Raymond JamesLower TargetOutperform$250.00 ➝ $225.00Low
11/5/2021Deutsche Bank AktiengesellschaftLower TargetBuy$250.00 ➝ $230.00High
11/4/2021StephensBoost TargetEqual Weight$178.00 ➝ $185.00Low
11/4/2021Royal Bank of CanadaLower TargetOutperform$244.00 ➝ $221.00Low
11/4/2021Credit Suisse GroupBoost TargetOutperform$192.00 ➝ $205.00Low
11/4/2021BMO Capital MarketsBoost TargetMarket Perform$180.00 ➝ $200.00Low
11/4/2021SVB LeerinkBoost TargetMarket Perform$170.00 ➝ $181.00Low
11/3/2021OppenheimerLower TargetOutperform$265.00 ➝ $225.00High
10/13/2021Truist FinancialLower TargetBuy$255.00 ➝ $190.00Medium
9/30/2021BMO Capital MarketsLower TargetNeutral ➝ Market Perform$240.00 ➝ $180.00Low
9/27/2021SVB LeerinkInitiated CoverageMarket Perform$170.00Low
9/23/2021UBS GroupInitiated CoverageSell$150.00High
9/17/2021OppenheimerReiterated RatingBuy$265.00Medium
9/9/2021CowenInitiated CoverageMarket Perform$195.00Medium
8/11/2021Credit Suisse GroupLower TargetOutperform$330.00 ➝ $250.00Medium
8/10/2021BenchmarkLower TargetBuy$325.00 ➝ $235.00Medium
8/9/2021Raymond JamesLower TargetOutperform$325.00 ➝ $250.00High
8/6/2021StephensLower TargetReduce ➝ Equal Weight$310.00 ➝ $237.00High
8/6/2021OppenheimerLower TargetOutperform$325.00 ➝ $265.00High
8/5/2021Bank of AmericaDowngradeBuy ➝ Neutral$220.00High
4/30/2021Royal Bank of CanadaBoost TargetOutperform$335.00 ➝ $350.00High
2/23/2021BenchmarkBoost TargetPositive ➝ Buy$275.00 ➝ $325.00Medium
2/8/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$275.00 ➝ $340.00Medium
1/5/2021Truist FinancialBoost Target$280.00 ➝ $325.00N/A
11/3/2020BarclaysBoost TargetOverweight$290.00 ➝ $298.00Medium
10/30/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$260.00 ➝ $275.00High
10/30/2020Credit Suisse GroupBoost TargetOutperform$246.00 ➝ $280.00High
9/21/2020OppenheimerBoost TargetOutperform$250.00 ➝ $260.00High
9/10/2020StephensReiterated RatingEqual Weight$235.00 ➝ $245.00Medium
9/2/2020BMO Capital MarketsBoost TargetMarket Perform$250.00 ➝ $270.00High
8/20/2020BarclaysInitiated CoverageOverweight$290.00 ➝ $290.00High
7/30/2020SunTrust BanksBoost TargetBuy$260.00 ➝ $270.00Medium
7/30/2020BenchmarkBoost TargetBuy$210.00 ➝ $250.00Medium
7/30/2020Royal Bank of CanadaBoost TargetOutperform$218.00 ➝ $260.00Medium
7/30/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$220.00 ➝ $260.00Medium
7/30/2020Raymond JamesBoost TargetOutperform$210.00 ➝ $255.00Medium
7/29/2020Jefferies Financial GroupBoost TargetBuy$225.00 ➝ $250.00Medium
7/10/2020SunTrust BanksBoost TargetBuy$240.00 ➝ $260.00Medium
6/18/2020BenchmarkUpgradeHold ➝ Buy$210.00High
5/21/2020SunTrust BanksBoost TargetBuy$225.00 ➝ $240.00High
5/11/2020UBS GroupLower TargetNeutral$208.00 ➝ $190.00Low
5/11/2020Raymond JamesLower TargetOutperform$225.00 ➝ $210.00Medium
5/10/2020Royal Bank of CanadaReiterated RatingBuy$218.00Medium
5/7/2020BenchmarkDowngradeBuy ➝ HoldHigh
4/27/2020OppenheimerReiterated RatingBuy$215.00Medium
3/9/2020BenchmarkUpgradeHold ➝ Buy$205.00High
2/21/2020StephensBoost TargetEqual Weight$180.00 ➝ $200.00Low
2/21/2020UBS GroupBoost TargetNeutral$154.00 ➝ $208.00Low
2/21/2020BMO Capital MarketsReiterated RatingMarket Perform$215.00Low
2/21/2020Credit Suisse GroupBoost TargetOutperform$206.00 ➝ $214.00Low
2/20/2020SunTrust BanksBoost TargetBuy$185.00 ➝ $225.00Low
2/20/2020Raymond JamesBoost TargetOutperform$200.00 ➝ $225.00Low
1/17/2020Credit Suisse GroupInitiated CoverageOutperform$206.00Low
1/3/2020Raymond JamesSet TargetOutperform$144.00 ➝ $200.00Medium
12/18/2019SunTrust BanksBoost TargetBuy$175.00 ➝ $185.00Low
12/6/2019BMO Capital MarketsInitiated CoverageMarket Perform$170.00Medium
11/26/2019Bank of AmericaBoost TargetBuy$170.00 ➝ $178.00Low
11/1/2019Robert W. BairdUpgradeNeutral ➝ Outperform$140.00 ➝ $160.00High
10/22/2019StephensReiterated RatingEqual Weight$145.00Low
10/21/2019StephensInitiated CoverageEqual Weight$145.00Low
9/16/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy$155.00Low
8/5/2019BarclaysBoost TargetEqual Weight$120.00 ➝ $125.00High
8/2/2019Royal Bank of CanadaBoost TargetOutperform$150.00Low
8/1/2019OppenheimerBoost Target$140.00 ➝ $150.00Low
7/15/2019Raymond JamesBoost TargetOutperform$140.00 ➝ $144.00Medium
7/8/2019Jefferies Financial GroupSet TargetBuy$150.00Low
5/2/2019Raymond JamesUpgradeMarket Perform ➝ Outperform$140.00High
3/21/2019BarclaysBoost TargetEqual Weight ➝ Equal Weight$115.00 ➝ $120.00Low
3/1/2019Craig HallumLower TargetHold$132.00 ➝ $124.00Low
3/1/2019SunTrust BanksBoost TargetBuy$145.00Low
2/5/2019BenchmarkDowngradeBuy ➝ Hold$136.64High
12/14/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$130.00High
11/16/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$126.00Medium
10/30/2018BenchmarkUpgradeHold ➝ Buy$125.00High
10/26/2018Craig HallumDowngradeBuy ➝ Hold$116.00 ➝ $104.00Medium
10/11/2018Robert W. BairdBoost TargetNeutral$105.00 ➝ $120.00High
10/11/2018SunTrust BanksBoost TargetBuy$130.00High
10/11/2018Cantor FitzgeraldBoost TargetNeutral$117.00 ➝ $125.00High
9/18/2018Bank of AmericaSet TargetBuy$139.00Low
9/13/2018Cantor FitzgeraldInitiated CoverageNeutral$117.00Low
8/3/2018Royal Bank of CanadaBoost TargetOutperform$115.00Medium
7/3/2018Bank of AmericaUpgradeNeutral ➝ Buy$88.00 ➝ $97.00Medium
6/5/2018Bank of AmericaBoost TargetNeutral ➝ Neutral$73.00 ➝ $78.00Medium
6/5/2018StephensReiterated RatingHold$78.00High
6/5/2018Robert W. BairdBoost TargetNeutral ➝ Neutral$67.00 ➝ $72.00High
5/9/2018Craig HallumBoost TargetBuy$60.00 ➝ $82.00Low
5/8/2018Robert W. BairdBoost TargetNeutral ➝ Neutral$66.00High
3/19/2018Royal Bank of CanadaUpgradeSector Perform ➝ OutperformLow
3/1/2018Robert W. BairdSet TargetNeutral ➝ Hold$60.00 ➝ $66.00Medium
3/1/2018OppenheimerBoost TargetOutperform$68.00 ➝ $63.00High
2/28/2018Jefferies Financial GroupSet TargetBuy$70.00Medium
(Data available from 1/27/2018 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 7 positive mentions
  • 8 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 7 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
  • 7 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 6 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 6 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Amedisys logo
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
Read More

Today's Range

Now: $91.16
Low: $90.00
High: $92.85

50 Day Range

MA: $86.51
Low: $80.12
High: $95.86

52 Week Range

Now: $91.16
Low: $79.30
High: $179.91


215,640 shs

Average Volume

422,231 shs

Market Capitalization

$2.96 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Amedisys?

The following Wall Street sell-side analysts have issued reports on Amedisys in the last year: Bank of America Co., Barclays PLC, Benchmark Co., BMO Capital Markets, Cowen Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Raymond James, Royal Bank of Canada, Stephens, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for AMED.

What is the current price target for Amedisys?

16 Wall Street analysts have set twelve-month price targets for Amedisys in the last year. Their average twelve-month price target is $128.25, suggesting a possible upside of 40.7%. BMO Capital Markets has the highest price target set, predicting AMED will reach $190.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $85.00 for Amedisys in the next year.
View the latest price targets for AMED.

What is the current consensus analyst rating for Amedisys?

Amedisys currently has 2 sell ratings, 4 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AMED, but not buy more shares or sell existing shares.
View the latest ratings for AMED.

What other companies compete with Amedisys?

How do I contact Amedisys' investor relations team?

Amedisys' physical mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider's listed phone number is (225) 292-2031 and its investor relations email address is [email protected] The official website for Amedisys is www.amedisys.com. Learn More about contacing Amedisys investor relations.